Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice
- PMID: 10717340
- DOI: 10.1016/s0264-410x(99)00565-4
Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice
Abstract
We have compared two types of plasmids for DNA immunization against HTLV-I envelope glycoproteins. One type of plasmid contains the coding DNA of the complete envelope gene of HTLV-I under the control of the CMV promoter with (CMVenvLTR) or without (CMVenv) the tax/rex genes. The second type contains the coding DNA of the complete env gene of HTLV-I under the control of the human desmin muscle specific promoter (DesEnv). These plasmids were inoculated into mice and the humoral response was studied by flow cytometry, ELISA and neutralization assays. Inoculation of the DesEnv construct elicited a higher humoral response with better neutralization properties than the injection of CMVenvLTR or CMVenv plasmids. The choice of vectors will be important for the design of genetic HTLV-I vaccines.
Similar articles
-
Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic and protein immunizations in mice.DNA Cell Biol. 1997 Dec;16(12):1439-48. doi: 10.1089/dna.1997.16.1439. DNA Cell Biol. 1997. PMID: 9428792
-
Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.Vaccine. 2000 Dec 8;19(9-10):1068-81. doi: 10.1016/s0264-410x(00)00340-6. Vaccine. 2000. PMID: 11137241
-
Immunologic analysis induced by DNA vaccine encoding E protein of Beijing-1 strain derived from Japanese encephalitis virus.Intervirology. 2007;50(2):93-8. doi: 10.1159/000097395. Epub 2006 Nov 30. Intervirology. 2007. PMID: 17139185
-
Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice.Curr Top Microbiol Immunol. 1998;226:79-89. doi: 10.1007/978-3-642-80475-5_6. Curr Top Microbiol Immunol. 1998. PMID: 9479837 Review. No abstract available.
-
DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1.Curr Top Microbiol Immunol. 1998;226:175-92. doi: 10.1007/978-3-642-80475-5_11. Curr Top Microbiol Immunol. 1998. PMID: 9479842 Review. No abstract available.
Cited by
-
HTLV-1 vaccination Landscape: Current developments and challenges.Vaccine X. 2024 Jul 16;19:100525. doi: 10.1016/j.jvacx.2024.100525. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39105133 Free PMC article. Review.
-
Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.BMC Infect Dis. 2023 May 11;23(1):320. doi: 10.1186/s12879-023-08289-7. BMC Infect Dis. 2023. PMID: 37170214 Free PMC article.
-
A role for an HTLV-1 vaccine?Front Immunol. 2022 Sep 8;13:953650. doi: 10.3389/fimmu.2022.953650. eCollection 2022. Front Immunol. 2022. PMID: 36159878 Free PMC article. Review.
-
Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).J Virol. 2001 Jul;75(13):5939-48. doi: 10.1128/JVI.75.13.5939-5948.2001. J Virol. 2001. PMID: 11390595 Free PMC article.
-
The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.Front Microbiol. 2022 May 4;13:897346. doi: 10.3389/fmicb.2022.897346. eCollection 2022. Front Microbiol. 2022. PMID: 35602078 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources